{
    "Symbol": "ALNY",
    "AssetType": "Common Stock",
    "Name": "Alnylam Pharmaceuticals Inc",
    "Description": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.",
    "CIK": "1178670",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-03-31",
    "MarketCapitalization": "33977014000",
    "EBITDA": "-122297000",
    "PERatio": "None",
    "PEGRatio": "-0.49",
    "BookValue": "-1.754",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "-2.63",
    "RevenuePerShareTTM": "15.97",
    "ProfitMargin": "-0.166",
    "OperatingMarginTTM": "-0.0879",
    "ReturnOnAssetsTTM": "-0.0305",
    "ReturnOnEquityTTM": "-15.01",
    "RevenueTTM": "2003335000",
    "GrossProfitTTM": "868601000",
    "DilutedEPSTTM": "-2.63",
    "QuarterlyEarningsGrowthYOY": "0",
    "QuarterlyRevenueGrowthYOY": "0.548",
    "AnalystTargetPrice": "270.06",
    "AnalystRatingStrongBuy": "8",
    "AnalystRatingBuy": "14",
    "AnalystRatingHold": "8",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "-",
    "ForwardPE": "-",
    "PriceToSalesRatioTTM": "10.27",
    "PriceToBookRatio": "142.92",
    "EVToRevenue": "9.65",
    "EVToEBITDA": "-81.96",
    "Beta": "0.37",
    "52WeekHigh": "274.93",
    "52WeekLow": "141.97",
    "50DayMovingAverage": "204.5",
    "200DayMovingAverage": "173.97",
    "SharesOutstanding": "126492000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}